Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD

About the trial

Sponsor

Yale University (with Brain & Behavior Research Foundation, National Center for Complementary and Integrative Health (NCCIH))

Tested

Magnetic Resonance Imaging (MRI) (procedure), PHNO (drug), calcitriol (dietary_supplement), Placebo oral capsule (drug), high-resolution research tomography (procedure), Dextro Amphetamine (drug)

Dates

Started 2017-08-15; completion 2023-01-17

Results posted

Yes

Specific Aim 1: As part of a within-subject, two-days, study design, to determine whether acute calcitriol (vs. placebo) pre-treatment is associated with greater amphetamine (Amp)-induced dopamine (DA) release in the caudate, putamen, ventral striatum (VST), and substantia nigra / ventral tegmental area (SN/VTA) of healthy human subjects. Specific Aim 2: To determine whether acute calcitriol (vs. placebo) pre-treatment is associated with better performance on a test of attention (e.g., the Continuous Performance Task or CPT-IP), after treatment with amphetamine. Hypothesis: Investigators hypothesize that Subjects pre-treated with calcitriol will have faster reaction times/higher accuracy …

From ClinicalTrials.gov, last updated 2024-03-19. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $2,550 in research payments for this study in 2025 (2 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.